Published: Mar 15, 2021 By Alex Keown
BSIP/UIG Via Getty Images
With more European countries pausing dosing of
AstraZeneca’s COVID-19 vaccine over concerns about potential blood clotting side effects, Russia is seeking to fill in the gaps with its Sputnik V vaccine.
Kirill Dmitriev, chief executive officer of Russian Direct Investment Fund, which has spearheaded Sputnik V, said RDIF has been coordinating with the governments of Italy, Spain, France and Germany to launch production of Sputnik V. This will bolster supplies of the vaccine to Europe once the preventative medication receives authorization from the European Medicines Agency.
“We are now actively working with EMA as part of the rolling review procedure. In addition, RDIF and partners are ready to start supplies to those EU countries that independently authorize Sputnik V,” Dmitriev said in an email to BioSpace.
Kraig Biocraft Laboratories Announces Expanded Spider Silk Protection with Patent Granted in Vietnam - read this article along with other careers information, tips and advice on BioSpace
Published: Mar 15, 2021
Demand for medical sterilization swabs is projected to witness steady growth during the forecast period 2020-2030. Medical sterilization is an important aspect for modern medical care to ensure the safety of patients from infection. Sterilization process kills the microorganisms residing on the equipments after use. There are various methods of sterilization such as autoenclaves, ETO, and Gamma radiation.
Sterile swab is an absorbent wipe mostly made of cotton or nonwoven fabric used to clean wounds, apply medication or for collecting biological samples. These swabs are bacteria free and help avoiding contamination and infection.
Growing Prevalence of Infectious Diseases
Published: Mar 15, 2021
Indiana-based radiopharmaceutical Contract Development and Manufacturing Organization expands nuclear pharmacy capabilities with second location
SpectronRx, a leading radiopharmaceutical contract development and manufacturing organization (CDMO), announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new Indianapolis, IN headquarters. The license also expands SpectronRx’s roster of authorized nuclear pharmacists and authorized users. The news comes as SpectronRx continues to scale its early-stage development and commercialization services for leading pharmaceutical companies working to develop and deploy radiopharmaceutical compounds for the treatment and detection of certain cancers and other diseases.
“Securing Nuclear Regulatory Commission materials licensing for our new headquarters and additional staff is a significant milestone for the growth of SpectronRx,” said John Zehner,
Published: Mar 15, 2021
March 15, 2021 11:00 UTC
Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for
the Company’s Lead Product Candidate Vicineum™
Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021
1
Marketing Authorization Application submitted in Europe with potential approval in early 2022
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year ended December 31, 2020. The Company’s lead program, Vicineum, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February 2021, the Food and Drug Administration (FDA) accepted for filing the Company s Biologi